Trial
NCT03462966
Rifaximin on Visceral Hypersensitivity
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Cedars-Sinai Medical Center
Collaborators
Bausch Health Americas, Inc.
Condition
Visceral Hypersensitivity
Intervention
Rifaximin
Why stopped
recruitment challenges
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-09-13